Ablexis is a technology company.
Ablexis is a technology company.
Ablexis has raised $12.0M across 1 funding round.
Ablexis has raised $12.0M in total across 1 funding round.
Ablexis has raised $12.0M in total across 1 funding round.
Ablexis's investors include Cure Ventures, Pfizer Venture Investments, Third Rock Ventures.
Ablexis, LLC is a biopharmaceutical technology company that develops and non-exclusively licenses the AlivaMab Mouse, a patented suite of next-generation transgenic mice serving as a platform for efficient human therapeutic antibody discovery.[1][2][3] It targets pharmaceutical and biotechnology companies by providing this technology via licensing agreements with dozens of partners, including global pharma firms, addressing the challenge of discovering high-quality antibody drug candidates with expanded immune responses, as seen in the newer AlivaMab-X Mouse.[1][2][3] The company raised $12M in seed/startup venture equity financing in May 2018 from Deerfield, and continues expanding its intellectual property, including U.S. patents like 10,492,476 on immunoglobulin locus engineering.[1][2]
Ablexis emerged as a biotech innovator focused on advancing transgenic mouse technology for antibody discovery, with its core product, the AlivaMab Mouse platform, developed as a unique, patented tool.[1][3] Key early milestones include securing seed/startup equity financing in May 2018 to support platform development and commercialization, followed by rapid adoption through non-exclusive licenses to dozens of companies, spanning global pharmaceuticals and private biotechs.[1][2] A pivotal moment came with announcements of IP expansion, such as new patents on AlivaMab Mouse engineering and the launch of AlivaMab-X for broader immune responses, solidifying its role in antibody R&D.[2][3]
Ablexis rides the wave of antibody therapeutics innovation, a booming sector driven by demand for novel biologics in oncology, immunology, and infectious diseases, where efficient discovery platforms are critical amid rising R&D costs.[1][2][3] Its timing aligns with advances in genetic engineering and transgenic models, enabling faster, more diverse antibody hits that accelerate drug pipelines for partners. Market forces like surging biologics approvals and biotech funding favor scalable platforms like AlivaMab, which democratize access via non-exclusive licenses, influencing the ecosystem by boosting collaborator success rates and indirectly advancing thousands of therapeutic programs.[1][3]
Ablexis is poised to deepen its dominance in transgenic antibody platforms through further IP builds and AlivaMab-X expansions, potentially capturing more licensing deals as AI-driven drug discovery and multispecific antibodies trend upward. Evolving influences include partnerships yielding blockbuster antibodies, amplifying its network effects in biotech. This positions Ablexis as an enduring enabler in human therapeutics, much like its foundational AlivaMab Mouse transformed early discovery workflows.[2][3]
Ablexis has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series A in June 2010.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2010 | $12.0M Series A | Cure Ventures, Pfizer Venture Investments, Third Rock Ventures |